H.C. Wainwright lowered the firm’s price target on Sanara MedTech (SMTI) to $36 from $54 and keeps a Buy rating on the shares following the Q3 report. The company plans to execute its commercial plan and improve operational efficiency to support sustainable revenue growth and improved profitability going forward, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMTI: